Home › NDC Lookup › RxCUI directory › RxCUI 1922453

5 ML cerliponase alfa 30 MG/ML Injection — RxCUI 1922453

RxNorm drug concept · Semantic clinical drug
RxCUI 1922453 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1922453
Official name5 ML cerliponase alfa 30 MG/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascerliponase alfa 150 MG per 5 ML Intraventricular Injection; cerliponase alfa 150 MG in 5 mL Intraventricular Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)105 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How 5 ML cerliponase alfa 30 MG/ML Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 5 ML cerliponase alfa 30 MG/ML Injection RxCUI 1922453

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Cerliponase 1922437
    • Cerliponase alfa 1922436
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Brineura 1922454
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cerliponase Injection 1922452
    • Cerliponase alfa Injection 2647003
    • Cerliponase Injectable Product 1922451
    • Cerliponase alfa Injectable Product 2660087
    • Cerliponase Injection [Brineura] 1922456
    • Cerliponase alfa Injection [Brineura] 2654385
    • Brineura Injectable Product 1922457
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cerliponase alfa 30 MG/ML SCDC · 1922450
  • Cerliponase Injection SCDF · 1922452
  • Cerliponase alfa Injection SCDFP · 2647003
  • Cerliponase Injectable Product SCDG · 1922451
  • Cerliponase alfa Injectable Product SCDGP · 2660087

Brand-Name Concepts

  • 5 ML cerliponase alfa 30 MG/ML Injection [Brineura] SBD · 1922458
  • Cerliponase alfa 30 MG/ML [Brineura] SBDC · 1922455
  • Cerliponase Injection [Brineura] SBDF · 1922456
  • Cerliponase alfa Injection [Brineura] SBDFP · 2654385
  • Brineura Injectable Product SBDG · 1922457
  • Brineura BN · 1922454

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1922453 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
68135-0811-02 1 KIT in 1 CARTON (68135-811-02) * 5 mL in 1 VIAL, GLASS (... Brineura BioMarin Pharmaceutical Inc. 2017-04-27
Observed labelers: BioMarin Pharmaceutical Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.